Naseem Zojwalla
Chief Tech/Sci/R&D Officer bei OLEMA PHARMACEUTICALS, INC.
Vermögen: 909 720 $ am 31.03.2024
Profil
Naseem Zojwalla currently works at Peloton Therapeutics, Inc., as Head-Clinical Development & Strategy, Turning Point Therapeutics, Inc., as Vice President-Clinical Development, Columbia University Medical Center, as Assistant Clinical Professor-Medicine, and Olema Pharmaceuticals, Inc., as Chief Medical Officer from 2022.
Dr. Zojwalla received her undergraduate degree from Stanford University and doctorate degree from Temple University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.03.2024 | 80 364 ( 0,14% ) | 909 720 $ | 31.03.2024 |
Aktive Positionen von Naseem Zojwalla
| Unternehmen | Position | Beginn |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31.01.2022 |
| TURG POIN | Chief Tech/Sci/R&D Officer | - |
| PELOTON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
| Columbia University Medical Center | Corporate Officer/Principal | - |
Ausbildung von Naseem Zojwalla
| Stanford University | Undergraduate Degree |
| Temple University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| OLEMA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Peloton Therapeutics, Inc.
 Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
